Literature DB >> 33706732

The role of serum β-trophin and endostatin in patients with polycystic ovary syndrome: Are they correlated?

Wei Gong1, Aikmu Bilixzi1, Xinmei Wang1, Yanli Lu1, Li Wan1, Lu Han2.   

Abstract

BACKGROUND: It's necessary to investigate the serum β-trophin and endostatin (ES) level and its influencing factors in patients with newly diagnosed polycystic ovary syndrome (PCOS).
METHODS: Newly diagnosed PCOS patients treated in our hospital were selected, and healthy women who took physical examination during the same period as healthy controls. We detected and compared the related serum indicators between two groups, Pearson correlation were conducted to identify the factors associated with β-trophin and ES, and the influencing factors of β-trophin and ES were analyzed by logistic regression.
RESULTS: A total of 62 PCOS patients and 65 healthy controls were included. The BMI, WHI, LH, FSH, TT, FAI, FBG, FINS, HOMA-IR, TC, TG, LDL, ES in PCOS patients were significantly higher than that of healthy controls, while the SHBG and HDL in PCOS patients were significantly lower than that of healthy controls (all p < 0.05). β-trophin was closely associated with BMI (r = 0.427), WHR (r = 0.504), FBG (r = 0.385), TG (r = 0.405) and LDL (r = 0.302, all p < 0.05), and ES was closely associated with BMI (r = 0.358), WHR (r = 0.421), FBG (r = 0.343), TC (r = 0.319), TG (r = 0.404, all p < 0.05). TG, BMI, WHR and FBG were the main factors affecting the serum β-trophin levels (all p < 0.05). FBG, TC and BMI were the main factors affecting the serum ES levels (all p < 0.05). The TG, β-trophin, ES level in PCOS patients with insulin resistance (IR) were significantly higher than that of those without IR (all p < 0.05).
CONCLUSION: Increased β-trophin is closely associated with increased ES in patients with PCOS, which may be the useful indicators for the management of PCOS.

Entities:  

Keywords:  Endostatin; Insulin resistance; Metabolism; Polycystic ovary syndrome; β-Trophin

Mesh:

Substances:

Year:  2021        PMID: 33706732      PMCID: PMC7953644          DOI: 10.1186/s12905-021-01198-4

Source DB:  PubMed          Journal:  BMC Womens Health        ISSN: 1472-6874            Impact factor:   2.809


  42 in total

1.  Inositol's and other nutraceuticals' synergistic actions counteract insulin resistance in polycystic ovarian syndrome and metabolic syndrome: state-of-the-art and future perspectives.

Authors:  Cristiana Paul; Antonio Simone Laganà; Paolo Maniglio; Onofrio Triolo; David M Brady
Journal:  Gynecol Endocrinol       Date:  2016-02-29       Impact factor: 2.260

2.  Serum β-trophin level as a new marker for noninvasive assessment of nonalcoholic fatty liver disease and liver fibrosis.

Authors:  Mustafa Cengiz; Seren Ozenirler; Murat Kocabiyik
Journal:  Eur J Gastroenterol Hepatol       Date:  2016-01       Impact factor: 2.566

3.  Polycystic ovarian syndrome: an under-recognised problem?

Authors:  Sarah C Hillman; Jeremy Dale
Journal:  Br J Gen Pract       Date:  2018-05       Impact factor: 5.386

Review 4.  Experts' opinion on inositols in treating polycystic ovary syndrome and non-insulin dependent diabetes mellitus: a further help for human reproduction and beyond.

Authors:  Fabio Facchinetti; Marialuisa Appetecchia; Cesare Aragona; Arturo Bevilacqua; Maria Salome Bezerra Espinola; Mariano Bizzarri; Rosario D'Anna; Didier Dewailly; Evanthia Diamanti-Kandarakis; Imelda Hernández Marín; Zdravko A Kamenov; Eleni Kandaraki; Antonio Simone Laganà; Giovanni Monastra; Mario Montanino Oliva; John E Nestler; Francesco Orio; Ali Cenk Ozay; Olga Papalou; Lali Pkhaladze; Giusy Porcaro; Nikos Prapas; Christophe O Soulage; Annarita Stringaro; Artur Wdowiak; Vittorio Unfer
Journal:  Expert Opin Drug Metab Toxicol       Date:  2020-03-19       Impact factor: 4.481

5.  Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.

Authors: 
Journal:  Fertil Steril       Date:  2004-01       Impact factor: 7.329

Review 6.  Ovarian angiogenesis in polycystic ovary syndrome.

Authors:  Mariana Di Pietro; Natalia Pascuali; Fernanda Parborell; Dalhia Abramovich
Journal:  Reproduction       Date:  2018-01-31       Impact factor: 3.906

Review 7.  Inositols in Polycystic Ovary Syndrome: An Overview on the Advances.

Authors:  Fabio Facchinetti; Vittorio Unfer; Didier Dewailly; Zdravko A Kamenov; Evanthia Diamanti-Kandarakis; Antonio Simone Laganà; John E Nestler; Christophe O Soulage
Journal:  Trends Endocrinol Metab       Date:  2020-03-09       Impact factor: 12.015

8.  Circulating betatrophin in healthy control and type 2 diabetic subjects and its association with metabolic parameters.

Authors:  Nasser M Al-Daghri; Shakilur Rahman; Shaun Sabico; Osama E Amer; Kaiser Wani; Mohammed Ghouse Ahmed Ansari; Omar S Al-Attas; Sudhesh Kumar; Majed S Alokail
Journal:  J Diabetes Complications       Date:  2016-05-31       Impact factor: 2.852

9.  Insulin upregulates betatrophin expression via PI3K/Akt pathway.

Authors:  Puhan Lu; Xi Chen; Zeqing Zhang; Jianhua Zhang; Yan Yang; Zhelong Liu; Junhui Xie; Shiying Shao; Xinrong Zhou; Shuhong Hu; Wentao He; Jiajun Zhao; Xuefeng Yu
Journal:  Sci Rep       Date:  2017-07-17       Impact factor: 4.379

10.  Elevated circulating lipasin/betatrophin in human type 2 diabetes and obesity.

Authors:  Zhiyao Fu; Feven Berhane; Alemu Fite; Berhane Seyoum; Abdul B Abou-Samra; Ren Zhang
Journal:  Sci Rep       Date:  2014-05-23       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.